source
- Novartis shareholder urges board overhaul after costly Avidity acquisition setbacksNovartis investor David Samra, managing director at Artisan Partners, told Reuters that the company’s board should be reshaped to improve oversight of its dealmaking activities. He said the board n…
- Encoded Therapeutics secures $275M Series F to advance gene therapy for Dravet syndromeEncoded Therapeutics announced a $275 million Series F financing round aimed at moving its lead gene‑therapy candidate, ETX101, toward pivotal trials for Dravet syndrome. In the ongoing Phase 1/2…